
CLAIMS

1. A compound of formula (I):



(I)


wherein:

R_{1a} is H or methyl;

R_{1b} is H or fluoro;

A is group (Aa), (Ab), (Ac) or (Ad):

wherein group (Aa) is:



(Aa);

wherein:

R_2 is H, C_{1-4}alkyl, C_{1-4}alkylene(aryl), C_{1-4}alkylene(OH), C_{1-4}alkylene(C_{3-6}cycloalkyl), C_{1-4}alkylene(4-7 membered heterocycloalkyl), C_{1-4}alkoxy, OC_{1-4}alkylene(aryl), C_{1-4}alkyleneOC_{1-4}alkyl, C_{1-4}alkyleneOC_{3-6}cycloalkyl, C_{1-4}alkyleneO(4-7 membered heterocycloalkyl), C_{1-4}alkyleneO(aryl), C_{3-6}alkynyl and C_{1-4}alkyleneO(C_{3-6}alkynyl);

wherein said aryl, heterocycloalkyl or cycloalkyl are optionally substituted by 1, 2 or 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{2a}R_{2b}$, SO_2R_{2c} and $NHSO_2R_{2c}$;

R_{2a} is selected from H and C_{1-4}alkyl;


R_{2b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

R_{2c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

each R_3 is independently halo, methyl, ethyl or n-propyl;

m is 0, 1, 2, 3 or 4;

wherein group (Ab) is:



(Ab);

wherein:

R_4 is H, C_{1-4}alkyl or C_{1-4}alkylene(aryl); wherein said aryl is optionally substituted by 1, 2 or 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{4a}R_{4b}$, SO_2R_{4c} and $NHSO_2R_{4c}$;

R_{4a} is selected from H and C_{1-4}alkyl;

R_{4b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;


R_{4c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

R_5 is H or C_{1-4}alkyl;

each R_6 is independently C_{1-4}alkyl or halo;

n is 0, 1, 2 or 3;

wherein group (Ac) is:




(Ac);

wherein:

R_7 is C_{1-4}alkyl, C_{1-4}alkylene(OH) or C_{1-4}alkyleneOC_{1-4}alkyl;

o is 1 or 2;

wherein group (Ad) is:



(Ad);

wherein:

X is a bond, O or CH_2;

each R_8 is independently halo, C_{1-4}alkyl, C_{1-4}alkoxy OC_{1-4}haloalkyl, OC_{1-4}alkylene(C_{3-6}cycloalkyl), OC_{1-4}alkylene(4-7 membered heterocycloalkyl) or OH; wherein said heterocycloalkyl and cycloalkyl are optionally substituted by 1, 2 or 3 substituents independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo, CN, OH, $NR_{8a}R_{8b}$, SO_2R_{8c} and $NHSO_2R_{8c}$;

R_{8a} is selected from H and C_{1-4}alkyl;

R_{8b} is selected from H, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;


R_{8c} is selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, aryl and 4-7 membered heterocycloalkyl;

each R_9 is independently halo or C_{1-4}alkyl;

p is 0, 1 or 2;

q is 0, 1, 2, 3 or 4;

wherein B is:



;

wherein:


R_{10} is H, halo or C_{1-4}alkyl;

D, E and F are each independently C(R_{10}); or one of D, E and F is N and the two remaining D, E and F groups are independently C(R_{10}); and

provided that the compound of formula (I) is not (E)-*N*-(3-fluoro-2-methylphenyl)-3-(1H-indazol-6-yl)acrylamide;

or a pharmaceutically acceptable salt and/or solvate thereof.

2. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is a compound of formula (I):



(I)


wherein:

R_{1a} is H or methyl;

R_{1b} is H or fluoro;

A is group (Aa), (Ab), (Ac) or (Ad):

wherein group (Aa) is:



(Aa);


wherein:

R_2 is H, C_{1-4}alkyl, C_{1-4}alkylene(aryl), C_{1-4}alkylene(OH), C_{1-4}alkylene(C_{3-6}cycloalkyl), C_{1-4}alkylene(4-7 membered heterocycloalkyl), C_{1-4}alkoxy, OC_{1-4}alkylene(aryl), C_{1-4}alkyleneOC_{1-4}alkyl, C_{1-4}alkyleneOC_{3-6}cycloalkyl, C_{1-4}alkyleneO(4-7 membered heterocycloalkyl), C_{1-4}alkyleneO(aryl), C_{3-6}alkynyl or C_{1-4}alkyleneO(C_{3-6}alkynyl); wherein said aryl, heterocycloalkyl or cycloalkyl may be optionally substituted by up to 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo and CN;

each R_3 is independently halo, methyl, ethyl or n-propyl;

m is 0, 1, 2, 3 or 4;

wherein group (Ab) is:



(Ab);

wherein:


R_4 is H, C_{1-4}alkyl or C_{1-4}alkylene(aryl); wherein said aryl may be optionally substituted by up to 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, halo and CN;

R_5 is H or C_{1-4}alkyl;

each R_6 is independently C_{1-4}alkyl or halo;

n is 0, 1, 2 or 3;

wherein group (Ac) is:




(Ac);

wherein:

R_7 is C_{1-4}alkyl, C_{1-4}alkylene(OH) or C_{1-4}alkyleneOC_{1-4}alkyl;

o is 1 or 2;

wherein group (Ad) is:



(Ad);

wherein:

X is a bond, O or CH_2;


each R_8 is independently halo, C_{1-4}alkyl, C_{1-4}alkoxy or OH;

each R_9 is independently halo or C_{1-4}alkyl;

p is 0, 1 or 2;

q is 0, 1, 2, 3 or 4;

wherein B is:



;

wherein:


R_{10} is H, halo or C_{1-4}alkyl; and

D, E and F are each independently C(R_{10}); or one of D, E and F is N and the two remaining D, E and F groups are independently C(R_{10});

provided that the compound of formula (I) is not (E)-*N*-(3-fluoro-2-methylphenyl)-3-(1H-indazol-6-yl)acrylamide;

or a pharmaceutically acceptable salt and/or solvate thereof.

3. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1 or 2, wherein A is group (Aa):



(Aa),


wherein:

R_2 is C_{1-4}alkyl, C_{1-4}alkylene(aryl), C_{1-4}alkylene(OH), C_{1-4}alkyleneOC_{1-4}alkyl, C_{1-4}alkyleneOC_{3-6}cycloalkyl, C_{1-4}alkyleneO(aryl), C_{1-4}alkylene(4-7 membered heterocycloalkyl), C_{1-4}alkyleneO(4-7 membered heterocycloalkyl) and C_{1-4}alkyleneO(C_{3-6}alkynyl); wherein said aryl, heterocycloalkyl or cycloalkyl may be optionally substituted by up to 3 substituents each independently selected from C_{1-4}alkyl, C_{3-6}cycloalkyl; C_{1-4}alkoxy, C_{1-4}haloalkyl, halo and CN;

each R_3 is independently fluoro or methyl; and

m is 1 or 2.


4. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1 or 2, wherein A is group (Ab):



(Ab).

5. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 4, wherein R_4 is H, methyl or benzyl, R^5 is H and n is 0.


6. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1 or 2, wherein A is group (Ac):



(Ac).

7. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 6, wherein R_7 is methyl, CH_2OH or CH_2OMe and o is 2.

8. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1 or 2, wherein A is group (Ad):




(Ad).

9. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 8, wherein X is a bond or O, p is 1 and R_8 is selected from methyl, OMe or fluoro.

10. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 8 or 9, wherein each R_9 is independently fluoro and q is 1 or 2.

11. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 10, wherein D, E and F are $C(R_{10})$ and each R_{10} is independently H, fluoro, chloro or methyl.

12. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is a compound of formula (Ia):




(Ia),

wherein A is group (Aa'), (AdI') or (AdII');

R_{10a} is H, fluoro, chloro or methyl;

wherein group (Aa') is:




(Aa');

wherein:

R_{2d} is methyl, CH_2OMe or $CH_2OCH_2C{\equiv}CH$;

each R_{3a} is independently H, methyl or fluoro; and

wherein group (AdI') is:




(AdI');

wherein:

R_{8d} is H, methyl or OMe;

R_{9a} is H or F;

wherein group (AdII') is:



(AdII'),

wherein:

X is O; and

$R_{8a'}$ is methyl;

provided that when A is group (AdI') and one of R_{10a} is fluoro or chloro, the two remaining R_{10a} groups are independently H;

or a pharmaceutically acceptable salt and/or solvate thereof.

13. The compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 1, which is selected from the group consisting of:

(E)-*N*-(3-fluoro-2-methylphenyl)-3-(7-methyl-1H-indazol-6-yl)acrylamide;

(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide;

(*R,E*)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide;

(E)-3-(1H-indazol-6-yl)-*N*-((1R,2R)-2-methylcyclohexyl) acrylamide (racemic mixture);

(E)-3-(1H-indazol-6-yl)-*N*-((1R,2R)-2-methylcyclohexyl) acrylamide (enantiomer 1);

(E)-3-(1H-indazol-6-yl)-*N*-((1R,2R)-2-methylcyclohexyl) acrylamide (enantiomer 2);

(E)-*N*-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-(6-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-(5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-(4-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(7-fluoro-1H-indazol-6-yl)acrylamide;

(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(5-fluoro-1H-indazol-6-yl)acrylamide;

(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(4-fluoro-1H-indazol-6-yl)acrylamide;

(E)-3-(5-chloro-1H-indazol-6-yl)-*N*-(2,3-dihydro-1H-inden-1-yl)acrylamide;

(E)-3-(4-chloro-1H-indazol-6-yl)-*N*-(2,3-dihydro-1H-inden-1-yl)acrylamide;

(E)-3-(1H-indazol-6-yl)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide (mixture of stereoisomers);

(E)-3-(1H-indazol-6-yl)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide (stereoisomer 1);

(E)-3-(1H-indazol-6-yl)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide (stereoisomer 2);

(E)-3-(1H-indazol-6-yl)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide (stereoisomer 3);

(E)-3-(1H-indazol-6-yl)-*N*-(2-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide (stereoisomer 4);

(E)-3-(1H-indazol-6-yl)-*N*-(3-methylchroman-4-yl)acrylamide (mixture of stereoisomers);

(E)-3-(1H-indazol-6-yl)-*N*-(3-methylchroman-4-yl)acrylamide (stereoisomer 1);

(E)-3-(1H-indazol-6-yl)-*N*-(3-methylchroman-4-yl)acrylamide (stereoisomer 2);

(E)-3-(1H-indazol-6-yl)-*N*-(3-methylchroman-4-yl)acrylamide (stereoisomer 3);

(E)-3-(1H-indazol-6-yl)-*N*-(3-methylchroman-4-yl)acrylamide (stereoisomer 4);

(E)-*N*-(2-(benzyloxy)phenyl)-3-(1H-indazol-6-yl)acrylamide;

(E)-3-(1H-indazol-6-yl)-*N*-(2-(phenoxymethyl)phenyl)acrylamide;

(E)-*N*-(2-(cyclobutoxymethyl)phenyl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-(1-benzyl-1H-indazol-7-yl)-3-(1H-indazol-6-yl)acrylamide;

(E)-3-(1H-indazol-6-yl)-*N*-(1-methyl-1H-indazol-7-yl)acrylamide;

(E)-3-(1H-indazol-6-yl)-*N*-(m-tolyl)acrylamide;

(E)-*N*-(3-chlorophenyl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-(3-fluorophenyl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-(2,6-dimethylphenyl)-3-(1H-indazol-6-yl)acrylamide;

(E)-*N*-((1R,3R)-3-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide (mixture of stereoisomers);
(E)-*N*-((1R,3R)-3-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide (stereoisomer 1);
(E)-*N*-((1R,3S)-3-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-6-yl)acrylamide (stereoisomer 2);
(E)-*N*-(2-(hydroxymethyl)phenyl)-3-(1H-indazol-6-yl)acrylamide;
(E)-*N*-(3-fluoro-2,6-dimethylphenyl)-3-(1H-indazol-6-yl)acrylamide;
(E)-3-(1H-indazol-6-yl)-*N*-(2-(methoxymethyl)phenyl)acrylamide;
(E)-*N*-(2-(((1-(2-fluoroethyl)azetidin-3-yl)oxy)methyl)phenyl)-3-(1H-indazol-6-yl)acrylamide hydrochloride;
(E)-*N*-(2-((3-fluoroazetidin-1-yl)methyl)phenyl)-3-(1H-indazol-6-yl)acrylamide;
(E)-*N*-(2-(2-(3-fluoroazetidin-1-yl)ethyl)phenyl)-3-(1H-indazol-6-yl)acrylamide;
(E)-*N*-(2-fluoro-6-methylphenyl)-3-(1H-indazol-6-yl)acrylamide;
(E)-*N*-(3-fluoro-2-methylphenyl)-3-(1H-pyrazolo[4,3-*b*]pyridin-6-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(1H-pyrazolo[4,3-*c*]pyridin-6-yl)acrylamide;
(E)-*N*-(2,3-dihydro-1H-inden-1-yl)-3-(1H-pyrazolo[3,4-*b*]pyridin-6-yl)acrylamide;
(E)-3-(1H-indazol-6-yl)-*N*-((1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-3-(1H-indazol-6-yl)-*N*-(7-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide;
(E)-3-(1H-indazol-6-yl)-*N*-(3-methyl-2,3-dihydro-1H-inden-1-yl)acrylamide; and
(E)-3-(1H-indazol-6-yl)-*N*-(2-((prop-2-yn-1-yloxy)methyl)phenyl)acrylamide;
or a pharmaceutically acceptable salt and/or solvate of any one thereof.

14. The compound, pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 13, for use as a pharmaceutical.

15. The compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 13, for use in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder in which inhibition of mPTP provides a therapeutic or prophylactic effect.

16. Use of the compound, pharmaceutically acceptable salt and/or solvate thereof according to claim 14, in the treatment or prophylaxis of a disease or disorder selected from degenerative or neurodegenerative diseases, disorders of the central nervous system, ischemia and re-perfusion injury, metabolic diseases, inflammatory or autoimmune diseases, diseases of aging and renal diseases, such as a degenerative or neurodegenerative disease selected from Parkinson's disease, dementia with Lewy bodies, Alzheimer's disease,

amyotrophic lateral sclerosis, multiple sclerosis, frontal temporal dementia, chemotherapy induced neuropathy, Huntington's disease, spinocerebellar ataxias, progressive supranuclear palsy, hereditary spastic paraplegia, Duchenne muscular dystrophy, congenital muscular dystrophy, traumatic brain injury and Friedreich's ataxia.

17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt and/or solvate thereof, and a pharmaceutically acceptable carrier or excipient.